Core Viewpoint - The company has focused on a core strategic direction of "rapamycin drug balloons + intravascular imaging + special balloons + vascular reduction" in its cardiovascular division over the past five years, with a key real-world study confirming the leading nature of this technology route [1] Group 1 - A significant real-world study presented at the 2025 TCT Global Interventional Cardiology Conference demonstrated that rapamycin drug balloons achieved non-inferior results compared to stents in a population with over 60% complex lesions and large vessel primary lesions [1] - The study results validate the industry trend of rapamycin drug balloons replacing traditional stents [1] - The company has made systematic arrangements for years, locking in on the rapamycin drug balloon direction while simultaneously developing supporting intravascular imaging and special balloons, creating a comprehensive advantage of "technology route + product matrix + ecological synergy" [1] Group 2 - In product development, the company has a richer new product layout in the coronary artery field compared to its peers, including future vascular reduction products that will be paired with drug balloons [1] - The medical device industry has transitioned from "imitation and following" to "original competition," necessitating deep clinical cooperation with hospitals for future research and development [1] - The company has established clinical cooperation projects with several top-ranked hospitals in the domestic coronary artery industry, maintaining a leading position in original research and development [1]

Core Viewpoint - The company emphasizes its focus on drug-coated balloons and specialized balloons as key development areas, highlighting the competitive advantage of rapamycin-based drug balloons [1] Group 1: Company Strategy - The company's development strategy aims to achieve integrated solutions while adhering to the concept of "intervention without implantation" [1] - The company plans to pursue both horizontal and vertical development, with horizontal development involving a range of product lines such as drug-coated balloons, specialized balloons, and intravascular imaging [1] - Vertical development focuses on the renewal and upgrading of existing products [1]